National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits in the top decile of US sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count).
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 490 sponsored US clinical trials, 50 recruiting.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors 490 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 398 completed. 69 of these trials are in Phase 3-4 (later-stage) and 178 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 25 trials.
Top-decile sponsor footprint
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ranks in the top decile of sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
398 of 424 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
490 total, page 1 of 10
Hepatic Lipid Metabolism-Alcohol Use Disorder
NCT07191561
Ketoconazole Effects on the Daily Cortisol Rhythm in Mild Autonomous Cortisol Secretion
NCT07649317
Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
NCT07142252
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
NCT07444723
Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study
NCT06730113
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
NCT06092333
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
NCT06635629
Pilot Study of Isocaloric Time Restricted Eating on Ketone Metabolism and Immunoregulation
NCT06169137
Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change
NCT06325722
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
NCT06223555
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate
NCT06044935
Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)
NCT05996536
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
NCT05832229
The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure
NCT05545306
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
NCT04685200
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
NCT05470504
A Natural History Study of Metabolic Sizing in Health and Disease
NCT05398783
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
NCT05419037
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
NCT05213598
Early Tracking of Childhood Health Determinants (ETCHED) Study
NCT03481829
Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake
NCT04799301
TReatment for ImmUne Mediated PathopHysiology
NCT04862221
Evaluation of Patients With Gastrointestinal Disease
NCT05041374
Natural History Study of Parathyroid Disorders
NCT04969926
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
NCT04927416
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
NCT03841617
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
NCT03884075
Study of Endocrine-Related Conditions and Physiology
NCT03867448
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
NCT03374215
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
NCT03049462
Evaluation of Adults With Endocrine and Metabolic-Related Conditions
NCT02830308
Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism
NCT02692885
Natural History of Noncirrhotic Portal Hypertension
NCT02417740
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
NCT02019706
New Heart Imaging Techniques to Evaluate Possible Heart Disease
NCT01399385
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
NCT00977977
Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
NCT01109420
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
NCT00739362
Natural History of Familial Carcinoid Tumor
NCT00646022
Blood Sampling for Research Related to Sickle Cell Disease
NCT00542230
Physical and Behavioral Traits of Overweight and Obese Adults
NCT00428987
Urinary Vitamin C Loss in Diabetic Subjects
NCT00071526
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
NCT00342927
Diabetes and Heart Disease Risk in Blacks
NCT00001853
Immune System Related Kidney Disease
NCT00001979
Evaluation of Patients With Liver Disease
NCT00001971
Diagnosing and Treating Low Blood Sugar Levels
NCT00001276
Studies on Tumors of the Thyroid
NCT00001160
Natural History of Thyroid Function Disorders
NCT00001159
Genetic Studies of Insulin and Diabetes
NCT00001987
What is open in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline
50 recruiting of 490 indexed (10% open); 398 completed (81%).
Phase mix: 69 late (III/IV) vs 178 early (I/II) (early-phase heavy).
Top condition: Obesity (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): open-pipeline peers nationwide
Peers matched on 490 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 490 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Mirati Therapeutics · 10% recruiting · 49 trials
- James J. Peters Veterans Affairs Medical Center · 10% recruiting · 39 trials
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
Related
What to do with this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) page
490 registered trials is a research-attention snapshot, not an endorsement of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or any single study.
- 50 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline card: 490 registered trials from official public datasets.Report a data error.